All questions
Clinical trials: Xolair (omalizumab) in allergic asthma
8 questions · 2 sources
Questions that apply to every indication of Xolair are on Xolair (omalizumab), all indications.
Clinical trials
How were the Xolair allergic asthma trials designed (Studies 1 and 2)?
Study results
How much did Xolair reduce asthma exacerbations vs placebo (Trials 1 and 2)?
Note: The table text lists each row's values in the header order: Asthma Trial 1 XOLAIR (N=268), Asthma Trial 1 placebo (N=257), Asthma Trial 2 XOLAIR (N=274), Asthma Trial 2 placebo (N=272). The stable steroid phase lasted 16 weeks and the steroid reduction phase 12 weeks.
Does Xolair improve asthma symptoms and FEV1 vs placebo (Trial 1)?
Note: Table 12 lists, for each endpoint, the XOLAIR mean baseline and median change to Week 16, then the placebo mean baseline and median change.
Does Xolair reduce asthma hospitalizations?
Did Xolair reduce exacerbations in severe asthma on high-dose steroids (Trial 3)?
Note: Table 13 lists each row's values in the header order: inhaled corticosteroids only, XOLAIR (N=126) and placebo (N=120); oral plus inhaled corticosteroids, XOLAIR (N=50) and placebo (N=45). Both phases lasted 16 weeks.
Which asthma patients did not have fewer exacerbations on Xolair?
Pediatric efficacy
How much did Xolair reduce exacerbations in children 6 to 11 (Trial 4)?
Did Xolair reduce exacerbations in children with well-controlled asthma (Trial 5)?
Note: The label describes Asthma Trial 5 as a study that primarily evaluated safety.